Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AVXS-101
AVXS-101
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Sat, 02/23/19 - 04:36 pm
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Novartis’ SMA Gene Therapy Is on the Fast Track for Approval
BioSpace
Mon, 12/3/18 - 05:55 pm
Novartis
gene therapy
SMA
AVXS-101
Zolgensma
priority review
FDA
US benefits manager baulks after Novartis values gene therapy at $4-5 mln
Yahoo/Reuters
Fri, 11/23/18 - 01:12 pm
Novartis
Express Scripts
SMA
spinal muscular atrophy
drug pricing
AVXS-101
Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
Endpoints
Tue, 11/6/18 - 12:27 am
Novartis
drug pricing
AVXS-101
spinal muscular atrophy
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
CP Wire
Wed, 04/25/18 - 10:29 pm
AveXis
Novartis
M&A
clinical trials
AVXS-101
gene therapy
spinal muscular atrophy
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Mon, 04/9/18 - 09:00 am
Novartis
M&A
AveXis
gene therapy
AVXS-101
SMA
spinal muscular atrophy
Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed
Investors Business Daily
Fri, 01/5/18 - 05:44 pm
Biogen
Spinraza
AveXis
AVXS-101
spinal muscular atrophy
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
Sun, 12/17/17 - 11:47 am
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
AveXis gets FDA nod for pivotal gene therapy trial
Biopharma Dive
Mon, 10/2/17 - 11:05 am
AveXis
FDA
gene therapy
AVXS-101